Everything below concerns c-Met signaling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
== Province-wide expansion and termination == In May 2022, Alberta Health Services signed a 15-year contract valued at approximately $4.8 billion with DynaLIFE to provide community laboratory services across Alberta. Province-wide service delivery began in December 2022. In August 2023, eight months after the transition, Alberta Health Services terminated the agreement at the request of DynaLIFE's owners and transferred the company's Alberta operations to Alberta Precision Laboratories. A 2025 examination by the Auditor General of Alberta found breakdowns in governance, due diligence, risk assessment and financial analysis. The examination found that the Minister and Department of Health expected Alberta Health Services to proceed despite concerns about projected savings, pressures associated with the COVID-19 pandemic and the presence of only one remaining bidder. Neither Alberta Health Services nor the Department of Health completed the required business case, and Alberta Health Services did not adequately evaluate the assumptions underlying DynaLIFE's financial proposal. The examination also found that Alberta Health Services and DynaLIFE proceeded with the transition while essential requirements, including laboratory information-system readiness, remained incomplete. A lack of shared operational planning contributed to increased wait times and diagnostic errors, and an above-average number of pathology-result errors compromised patients. The Auditor General attributed $77 million in non-value-added costs to the unsuccessful outsourcing initiative.
In June 1789, the regiment was formed in England as a permanent unit to relieve the New South Wales Marine Corps, who had accompanied the First Fleet to Australia. The regiment began arriving as guards on the Second Fleet in 1790. The regiment, led by Major Francis Grose, consisted of three companies, numbering about 300 men. Although drafts were sent from Britain to reinforce the regiment throughout its time in Australia, its full strength never exceeded 500. A fourth company was raised from those Marines wishing to remain in New South Wales under Captain George Johnston, who had been Governor Arthur Phillip's aide-de-camp. In December 1792, when Phillip returned to England for respite, Grose was left in charge. Grose immediately abandoned Phillip's plans for governing the colony. A staunch military man, he established military rule and set out to secure the authority of the Corps. He abolished the civilian courts and transferred the magistrates to the authority of Captain Joseph Foveaux. After the poor crops of 1793 he cut the rations of the convicts but not those of the Corps, overturning Phillip's policy of equal rations for all. In a connived attempt to improve agricultural production and make the colony more self-sufficient, Grose turned away from collective farming and made generous land grants to officers of the Corps. They were also provided with government-fed and clothed convicts as farm labour.
Rather, the tRNA-bound seryl residue is converted to a selenocysteine residue by the pyridoxal phosphate-containing enzyme selenocysteine synthase. In eukaryotes and archaea, two enzymes are required to convert tRNA-bound seryl residue into tRNA selenocysteinyl residue: PSTK (O-phosphoseryl-tRNA[Ser]Sec kinase) and selenocysteine synthase. Finally, the resulting Sec-tRNASecis specifically bound to an alternative translational elongation factor (SelB or mSelB (or eEFSec)), which delivers it in a targeted manner to the ribosomes translating mRNAs for selenoproteins. The specificity of this delivery mechanism is brought about by the presence of an extra protein domain (in bacteria, SelB) or an extra subunit (SBP2 for eukaryotic mSelB/eEFSec) which bind to the corresponding RNA secondary structures formed by the SECIS elements in selenoprotein mRNAs.
=== Matrix === The matrix system has a drug layer of a semisolid matrix containing a drug solution or suspension. The adhesive layer in this patch surrounds the drug layer, partially overlaying it. The release rate is determined by the physical properties of the matrix. Also known as a monolithic device. Limited research indicates that it may be possible to cut some matrix patches to provide lower doses, provided the cut part not immediately used is stored at cool temperatures.
In development, the viability of the process on a semi-commercial scale has to be demonstrated. Trial quantities of the new fine chemical have to be manufactured for market development, clinical tests, and other requirements. The necessary data has to be generated in order to enable the engineering department to plan the modifications of the industrial-scale plant and in order to calculate production costs for the expected large-volume requirements. Both equipment and plant layout of the pilot plant reflect those of an industrial multipurpose plant, except for the size of reaction vessels (bench-scale laboratory ~10–60 liters; pilot plant ~100–2500 liters) and the degree of process automation. Before the process is ready for transfer to the industrial-scale plant, the following activities have to be completed: adaptation of the laboratory process to the constraints of a pilot plant, hazard and operability (HAZOP) analysis, and execution of demonstration batches. The main differences between laboratory synthesis and industrial scale production are shown in Table 4.
Sources: en.wikipedia.org
== History == Originally, injectable bulking agents were used to treat stress urinary incontinence in females. The procedure aimed to bulk out the tissues of the neck of the bladder, and it was successful. The technique was first used for FI in 1993 by an Egyptian surgeon. He used polytetrafluroethylene (PTFE/polytef/Teflon) paste injected into the submucosal layer of anal canal. Later publications described autologous transplantation of fat from the abdominal wall or the buttock. After about the year 2000, many different materials started to be used as well as variations of the technique. Some of these materials were concurrently being used to treat urinary incontinence. The latest development of this technique is the implantable bulking agents "Gatekeeper" and "Sphinkeeper". These are not injectable materials but rather implants which expand after placement. As such, they are termed "self-expandable prostheses", and the term "non-self-expandable prostheses" is used to refer to older injectable materials.
The third specimen previously assigned to Sinosauropteryx most likely represents a tyrannosauroid unrelated to this genus. The second, S. lingyuanensis, is known from a single specimen, named after its type locality. Sinosauropteryx lived in what is now northeastern China during the early Cretaceous period. It was among the first dinosaurs discovered from the Yixian Formation in Liaoning Province, and was a member of the Jehol Biota. Well-preserved fossils of this genus illustrate many aspects of its biology, such as its diet and reproduction.
=== Chemical === Like all actinides, berkelium dissolves in various aqueous inorganic acids, liberating gaseous hydrogen and converting into the berkelium(III) state. This trivalent oxidation state (+3) is the most stable, especially in aqueous solutions, but tetravalent (+4), pentavalent (+5), and possibly divalent (+2) berkelium compounds are also known. The existence of divalent berkelium salts is uncertain and has only been reported in mixed lanthanum(III) chloride-strontium chloride melts. A similar behavior is observed for the lanthanide analogue of berkelium, terbium. Aqueous solutions of Bk3+ ions are green in most acids. The color of Bk4+ ions is yellow in hydrochloric acid and orange-yellow in sulfuric acid. Berkelium does not react rapidly with oxygen at room temperature, possibly due to the formation of a protective oxide layer surface. However, it reacts with molten metals, hydrogen, halogens, chalcogens and pnictogens to form various binary compounds. In 2025 an organometallic compound containing berkelium was synthesized from 0.3 mg of berkelium and named berkelocene.
== Early modern period == In the 15th century, Catanzaro was exporting its silk cloth and its technical skills to neighbouring Sicily. By the middle of the century, silk spinning had achieved scale in Catanzaro. Catanzaro's silk industry supplied almost all of Europe and was sold at large fairs to Spanish, Venetian, Genoan, Florentine, and Dutch merchants. The city was famous for its manufacture of silks, velvets, damasks and brocades. In 1519, Emperor Charles V formally recognized the growth of Catanzaro's silk industry, allowing the city to establish a consulate of silk crafts, charged with regulating and controlling the various stages of a production that flourished throughout the 16th century. In 1442, the Aragonese took control under Alfonso V of Aragon who became ruler under the Crown of Aragon. In 1501 Calabria came under the control of Ferdinand II of Aragon, whose wife Queen Isabella of Castille is famed for sponsoring the first voyage of Christopher Columbus in 1492. Calabria suffered under Aragonese rule with heavy taxes, feuding landlords, starvation, and sickness. After a brief period in the early 1700s under the Habsburgs, Calabria came under the control of the Spanish Bourbons in 1735. During the 16th century Calabrian doctor and astronomer Luigi Lilio created the Gregorian calendar. In 1466, King Louis XI decided to develop a national silk industry in Lyon and employed many Italian workers, mainly from Calabria. The fame of the master weavers of Catanzaro spread throughout France. They were invited to Lyon to teach the techniques of weaving.
== Background == By the mid-1790s, Humboldt had devoted himself wholly to scientific investigations. Despite being offered a promotion and an increase in pay, he resigned his position as a mining official in the Prussian civil service in order to embark on a journey that would “advance him scientifically.” To the Minister of Mines in Berlin Humboldt declared: "I am considering a complete change in my mode of life, and I intend to withdraw from any official position with the state." His health, he claimed, had suffered. All he had wanted was to prepare himself for a scientific expedition by a practical employment in the mines. "As I have a deep conviction that such an expedition is highly important for increasing our knowledge of geology and physical science, I am exceedingly eager to devote my energies immediately to this end. After his mother's death in 1796, Humboldt inherited the financial means to pursue independent explorations. He decided to go to Italy, where he wanted to spend a year to a year and a half researching volcanoes. From there, he wanted to travel via Paris to England, where he would board a ship to the West Indies. However, the political instability caused by Napoleon's Italian campaign in 1797 forced Humboldt to cancel his plans. In May 1798, Humboldt traveled to Paris, where he met the botanist Aimé Bonpland. After their attempt to travel to Egypt had once again failed due to Napoleon and his campaign there, the two decided to go to Madrid in December 1798.
Sources: en.wikipedia.org
==== Leishmaniasis ==== Upon phagocytosis by a macrophage, the Leishmania parasite finds itself in a phagocytic vacuole. Under normal circumstances, this phagocytic vacuole would develop into a lysosome and its contents would be digested. Leishmania alter this process and avoid being destroyed; instead, they make a home inside the vacuole.
(SC) subcutaneous (most applicable to real bites): 0.32 mg/kg, 0.28 mg/kg. (IV) intravenous: 0.25 mg/kg, 0.011 mg/kg. (IP) intraperitoneal: 0.30 mg/kg (average), 0.941 mg/kg. 0.05 mg/kg (the last quote does not make it clear if it is either intravenous or intraperitoneal). It is estimated that only 10 to 15 mg will kill a human adult; however, its bites deliver about 120 mg of venom on average, although they may deliver up to 400 mg of venom in a single bite. Severe neurotoxicity invariably ensues rapidly. This is because of several factors, including the high potency of the venom, and the unusual composition of synergistic toxins contained within the venom, which bring on severe symptoms of envenomation and death much faster than any other snake venom. In addition, the snake itself possesses the most advanced, evolved, and efficient venom delivery apparatus among all venomous snakes, and the most advanced and evolved dentition of all elapids. Black mambas possess the longest fangs of any elapid, which average around 13.1 millimeters (0.52 in), but may grow as long as 22 millimeters (0.87 in). Another feature that distinguishes the dentition and venom delivery apparatus of this species from all other elapids, as well as other species of venomous snake including those of the family Viperidae, is that the fangs are positioned well forward at the most anterior position possible in its mouth – right up in the front of the upper jaw.
== Capture of Constantinople == When the Nicaean force reached the village of Selymbria, some 30 miles (48 km) west of Constantinople, they learned from some independent local farmers (thelematarioi) that the entire Latin garrison, as well as the Latin-allied Venetian fleet, was absent conducting a raid against the Nicaean island of Daphnousia in the Black Sea. Strategopoulos initially hesitated to take advantage of the situation, fearing that his small force might be destroyed if the Latin army returned too soon, and because he would exceed the provisions of the emperor's orders, but eventually decided he could not squander such a remarkable opportunity to seize the city without a prolonged siege.
Ants are eusocial insects of the family Formicidae and, along with the related wasps and bees, belong to the order Hymenoptera. Ants evolved from vespoid wasp ancestors in the Cretaceous period. More than 13,800 of an estimated total of 22,000 species have been described. They are easily identified by their geniculate (elbowed) antennae and the distinctive node-like structure that forms their slender waists. Ants form colonies that range in size from a few dozen individuals often living in small natural cavities to highly organised colonies that may occupy large territories with a sizeable nest (or nests) that consist of millions of individuals. In some cases they reach hundreds of millions of individuals in super colonies. Typical colonies consist of various castes of sterile, wingless females, most of which are workers (ergates), as well as soldiers (dinergates) and other specialised groups. Nearly all ant colonies also have some fertile males called "drones" and one or more fertile females called "queens" (gynes). The colonies are described as superorganisms because the ants appear to operate as a unified entity, collectively working together to support the colony. Ants have colonised almost every landmass on Earth. The only places lacking indigenous ants are Antarctica and a few remote or inhospitable islands. Ants thrive in moist tropical ecosystems and may exceed the combined biomass of wild birds and mammals.
Peptide receptor radionuclide therapy (PRRT) is a type of radionuclide therapy, using a radiopharmaceutical that targets peptide receptors to deliver localised treatment, typically for neuroendocrine tumours (NETs).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.